Close

Cookies on this website

We use cookies to ensure that we give you the best experience on our website. By continuing to browse this site, you are agreeing to our use of cookies.

Continue Find out more

23 Feb 2012
PDMR Share Dealings

February 23, 2012 – Shire plc (LSE: SHP, NASDAQ: SHPGY), the global specialty biopharmaceutical company announces the following dealings by Persons Discharging Managerial Responsibility (“PDMRs”) in American Depository Shares (“ADSs”). One ADS is equal to three Shire plc ordinary shares of 5p.

Release of Performance Share Awards (“PSA Awards”)
In accordance with the rules of the Portfolio Share Plan (“PSP”), the following ADSs were released on February 20, 2012 in connection with PSA Awards granted in 2009 under Part B of the PSP. The Company was notified today that sufficient ADSs were sold on February 21, 2012 to satisfy the personal tax liabilities of each PDMR.

 No of ADSs releasedNo of ADSs soldAverage sale price
Michael Cola15,263
6,329$104.1994
Barbara Deptula9,158 3,949$104.1994
Sylvie Gregoire15,2635,649$104.1994


Exercise of Stock Appreciation Right Awards (“SAR Awards”)

The Company was notified today that the following SAR Awards, which were granted under Part A of the PSP, were exercised on February 22, 2012.

 No of ADSs exercisedExercise priceNo of ADSs receivedNo of ADSs sold
Sale price
Michael Cola
20,000$38.6312,70412,704 $105.4991
Barbara Deptula12,000$38.637,6267,626 $106.00


This notification relates to disclosures made in accordance with 3.1.4(R)(1)(a) of the Disclosure and Transparency Rules.

Tony Guthrie
Deputy Company Secretary

For further information please contact:

Investor Relations
Eric Rojas (erojas@shire.com)
+1 781 482 0999

Sarah Elton-Farr (seltonfarr@shire.com)
+44 1256 894157

Notes to editors

SHIRE PLC

Shire’s strategic goal is to become the leading specialty biopharmaceutical company that focuses on meeting the needs of the specialist physician. Shire focuses its business on attention deficit hyperactivity disorder, human genetic therapies, gastrointestinal diseases and regenerative medicine as well as opportunities in other therapeutic areas to the extent they arise through acquisitions.

Shire’s in-licensing, merger and acquisition efforts are focused on products in specialist markets with strong intellectual property protection and global rights. Shire believes that a carefully selected and balanced portfolio of products with strategically aligned and relatively small-scale sales forces will deliver strong results.

For further information on Shire, please visit the Company’s website: www.shire.com.

« Back to Shire news

Did you know...

You can sign up to receive email and SMS alerts so that you can keep up to speed with our latest news.

Email and SMS alerts

Did you know...

We donated over $35,000 in
outdated laboratory
equipment
to local
schools?